1
|
Kayser G, Csanadi A, Kakanou S, Prasse A,
Kassem A, Stickeler E, Passlick B and Zur Hausen A: Downregulation
of MTSS1 expression is an independent prognosticator in squamous
cell carcinoma of the lung. Br J Cancer. 112:866–873. 2015.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Chang A: Chemotherapy, chemoresistance and
the changing treatment landscape for NSCLC. Lung Cancer. 71:3–10.
2011. View Article : Google Scholar
|
3
|
Ling DJ, Chen ZS, Liao QD, Feng JX, Zhang
XY and Yin TY: Differential effects of MTSS1 on invasion and
proliferation in subtypes of non-small cell lung cancer cells. Exp
Ther Med. 12:1225–1231. 2016. View Article : Google Scholar : PubMed/NCBI
|
4
|
McNeill PM, Wagman LD and Neifeld JP:
Small bowel metastases from primary carcinoma of the lung. Cancer.
59:1486–1489. 1987. View Article : Google Scholar : PubMed/NCBI
|
5
|
Downey RJ, Asakura S, Deschamps C and
Colby TV: Large cell carcinoma of the lung: Results of resection
for a cure. J Thorac Cardiovasc Surg. 117:599–604. 1999. View Article : Google Scholar : PubMed/NCBI
|
6
|
Wall ME, Wani MC, Cook CE, Palmer KH,
McPhail AT and Sim GA: Plant antitumor agents. 1. The isolation and
structure of camptothecin, a novel alkaloidal leukemia and tumor
inhibitor from Camptotheca acuminata. J Am Chem Soc. 88:3888–3890.
1966. View Article : Google Scholar
|
7
|
Wadkins RM, Bearss D, Manikumar G, Wani
MC, Wall ME and Von Hoff DD: Topoisomerase I-DNA complex stability
induced by camptothecins and its role in drug activity. Curr Med
Chem Anticancer Agents. 4:327–334. 2004. View Article : Google Scholar : PubMed/NCBI
|
8
|
Chou HL, Fong Y, Wei CK, Tsai EM, Chen JY,
Chang WT, Wu CY, Huang HW and Chiu CC: A quinone-containing
compound enhances camptothecin-induced apoptosis of lung cancer
through modulating endogenous ROS and ERK signaling. Arch Immunol
Ther Exp (Warsz). 65:241–252. 2017. View Article : Google Scholar
|
9
|
Kawakami T, Machida N, Yasui H, Kawahira
M, Kawai S, Kito Y, Yoshida Y, Hamauchi S, Tsushima T, Todaka A, et
al: Efficacy and safety of irinotecan monotherapy as third-line
treatment for advanced gastric cancer. Cancer Chemother Pharmacol.
78:809–814. 2016. View Article : Google Scholar : PubMed/NCBI
|
10
|
Kim M, Keam B, Kim TM, Kim HG, Kim JS, Lee
SS, Shin SH, Kim MK, Park KU, Kim DW, et al: Phase II study of
irinotecan and cisplatin combination chemotherapy in metastatic,
unresectable esophageal cancer. Cancer Res Treat. 49:416–422. 2017.
View Article : Google Scholar :
|
11
|
Zhang B, Wang T, Yang S, Xiao Y, Song Y,
Zhang N and Garg S: Development and evaluation of oxaliplatin and
irinotecan co-loaded liposomes for enhanced colorectal cancer
therapy. J Control Release. 238:10–21. 2016. View Article : Google Scholar : PubMed/NCBI
|
12
|
Keyvani-Ghamsari S, Rabbani-Chadegani A,
Sargolzaei J and Shahhoseini M: Effect of irinotecan on HMGB1, MMP9
expression, cell cycle, and cell growth in breast cancer (MCF-7)
cells. Tumour Biol. 39:10104283176983542017. View Article : Google Scholar : PubMed/NCBI
|
13
|
Bruchim I, Ben-Harim Z, Piura E, Haran G
and Fishman A: Analysis of two topotecan treatment schedules in
patients with recurrent ovarian cancer. J Chemother. 28:129–134.
2016. View Article : Google Scholar : PubMed/NCBI
|
14
|
Kubo T, Fujiwara K, Hotta K, Okada T,
Kuyama S, Harita S, Ninomiya T, Kamei H, Hosokawa S, Bessho A, et
al: A phase II study of topotecan and cisplatin with sequential
thoracic radiotherapy in elderly patients with small-cell lung
cancer: Okayama Lung Cancer Study Group 0102. Cancer Chemother
Pharmacol. 78:769–774. 2016. View Article : Google Scholar : PubMed/NCBI
|
15
|
Yang XQ, Li CY, Xu MF, Zhao H and Wang D:
Comparison of first-line chemotherapy based on irinotecan or other
drugs to treat non-small cell lung cancer in stage IIIB/IV: A
systematic review and meta-analysis. BMC Cancer. 15:9492015.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Sugimoto Y, Tsukahara S, Oh-hara T, Isoe T
and Tsuruo T: Decreased expression of DNA topoisomerase I in
camptothecin- resistant tumor cell lines as determined by a
monoclonal antibody. Cancer Res. 50:6925–6930. 1990.PubMed/NCBI
|
17
|
Kawabata S, Oka M, Shiozawa K, Tsukamoto
K, Nakatomi K, Soda H, Fukuda M, Ikegami Y, Sugahara K, Yamada Y,
et al: Breast cancer resistance protein directly confers SN-38
resistance of lung cancer cells. Biochem Biophys Res Commun.
280:1216–1223. 2001. View Article : Google Scholar : PubMed/NCBI
|
18
|
Feeney GP, Errington RJ, Wiltshire M,
Marquez N, Chappell SC and Smith PJ: Tracking the cell cycle
origins for escape from topotecan action by breast cancer cells. Br
J Cancer. 88:1310–1317. 2003. View Article : Google Scholar
|
19
|
Han JY, Lim HS, Yoo YK, Shin ES, Park YH,
Lee SY, Lee JE, Lee DH, Kim HT and Lee JS: Associations of ABCB1,
ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and
clinical outcome in patients with advanced non-small cell lung
cancer. Cancer. 110:138–147. 2007. View Article : Google Scholar : PubMed/NCBI
|
20
|
Czarny P, Pawlowska E, Bialkowska-Warzecha
J, Kaarniranta K and Blasiak J: Autophagy in DNA damage response.
Int J Mol Sci. 16:2641–2662. 2015. View Article : Google Scholar : PubMed/NCBI
|
21
|
Song X, Narzt MS, Nagelreiter IM,
Hohensinner P, Terlecki-Zaniewicz L, Tschachler E, Grillari J and
Gruber F: Autophagy deficient keratinocytes display increased DNA
damage, senescence and aberrant lipid composition after oxidative
stress in vitro and in vivo. Redox Biol. 11:219–230. 2017.
View Article : Google Scholar :
|
22
|
Maiuri MC, Zalckvar E, Kimchi A and
Kroemer G: Self-eating and self-killing: Crosstalk between
autophagy and apoptosis. Nat Rev Mol Cell Biol. 8:741–752. 2007.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Liang B, Liu X, Liu Y, Kong D, Liu X,
Zhong R and Ma S: Inhibition of autophagy sensitizes MDR-phenotype
ovarian cancer SKVCR cells to chemotherapy. Biomed Pharmacother.
82:98–105. 2016. View Article : Google Scholar : PubMed/NCBI
|
24
|
Lu Y, Liu LL, Liu SS, Fang ZG, Zou Y, Deng
XB, Long ZJ, Liu Q and Lin DJ: Celecoxib suppresses autophagy and
enhances cytotoxicity of imatinib in imatinib-resistant chronic
myeloid leukemia cells. J Transl Med. 14:2702016. View Article : Google Scholar : PubMed/NCBI
|
25
|
Vazquez-Martin A, Oliveras-Ferraros C and
Menendez JA: Autophagy facilitates the development of breast cancer
resistance to the anti-HER2 monoclonal antibody trastuzumab. PLoS
One. 4:e62512009. View Article : Google Scholar : PubMed/NCBI
|
26
|
Chiu CC, Chou HL, Chen BH, Chang KF, Tseng
CH, Fong Y, Fu TF, Chang HW, Wu CY, Tsai EM, et al: BPIQ, a novel
synthetic quinoline derivative, inhibits growth and induces
mitochondrial apoptosis of lung cancer cells in vitro and in
zebrafish xenograft model. BMC Cancer. 15:9622015. View Article : Google Scholar : PubMed/NCBI
|
27
|
Chiu CC, Liu PL, Huang KJ, Wang HM, Chang
KF, Chou CK, Chang FR, Chong IW, Fang K, Chen JS, et al:
Goniothalamin inhibits growth of human lung cancer cells through
DNA damage, apoptosis, and reduced migration ability. J Agric Food
Chem. 59:4288–4293. 2011. View Article : Google Scholar : PubMed/NCBI
|
28
|
Tsai JR, Chong IW, Chen YH, Hwang JJ, Yin
WH, Chen HL, Chou SH, Chiu CC and Liu PL: Magnolol induces
apoptosis via caspase-independent pathways in non-small cell lung
cancer cells. Arch Pharm Res. 37:548–557. 2014. View Article : Google Scholar
|
29
|
Tung YT, Hsu WM, Lee H, Huang WP and Liao
YF: The evolutionarily conserved interaction between LC3 and p62
selectively mediates autophagy-dependent degradation of mutant
huntingtin. Cell Mol Neurobiol. 30:795–806. 2010. View Article : Google Scholar : PubMed/NCBI
|
30
|
Ciechomska IA and Tolkovsky AM:
Non-autophagic GFP-LC3 puncta induced by saponin and other
detergents. Autophagy. 3:586–590. 2007. View Article : Google Scholar : PubMed/NCBI
|
31
|
Saeki T, Mhashilkar A, Chada S, Branch C,
Roth JA and Ramesh R: Tumor-suppressive effects by
adenovirus-mediated mda-7 gene transfer in non-small cell lung
cancer cell in vitro. Gene Ther. 7:2051–2057. 2000. View Article : Google Scholar
|
32
|
Ramnath N, Yu J, Khushalani NI, Gottlieb
RH, Schwarz JK, Iyer RV, Rustum YM and Creaven PJ: Scheduled
administration of low dose irinotecan before gemcitabine in the
second line therapy of non-small cell lung cancer: A phase II
study. Anticancer Drugs. 19:749–752. 2008. View Article : Google Scholar : PubMed/NCBI
|
33
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View Article : Google Scholar : PubMed/NCBI
|
34
|
Fukuda T, Oda K, Wada-Hiraike O, Sone K,
Inaba K, Ikeda Y, Makii C, Miyasaka A, Kashiyama T, Tanikawa M, et
al: Autophagy inhibition augments resveratrol-induced apoptosis in
Ishikawa endometrial cancer cells. Oncol Lett. 12:2560–2566. 2016.
View Article : Google Scholar : PubMed/NCBI
|
35
|
Sánchez-Flores M, Pásaro E, Bonassi S,
Laffon B and Valdiglesias V: γH2AX assay as DNA damage biomarker
for human population studies: Defining experimental conditions.
Toxicol Sci. 144:406–413. 2015. View Article : Google Scholar
|
36
|
Galhardo RS, Hastings PJ and Rosenberg SM:
Mutation as a stress response and the regulation of evolvability.
Crit Rev Biochem Mol Biol. 42:399–435. 2007. View Article : Google Scholar : PubMed/NCBI
|
37
|
Yamagata T, Kusuhara H, Morishita M,
Takayama K, Benameur H and Sugiyama Y: Improvement of the oral drug
absorption of topotecan through the inhibition of intestinal
xenobiotic efflux transporter, breast cancer resistance protein, by
excipients. Drug Metab Dispos. 35:1142–1148. 2007. View Article : Google Scholar : PubMed/NCBI
|
38
|
Furukawa Y and Kikuchi J: Epigenetic
mechanisms of cell adhesion-mediated drug resistance in multiple
myeloma. Int J Hematol. 104:281–292. 2016. View Article : Google Scholar : PubMed/NCBI
|
39
|
Yan LH, Wang XT, Yang J, Lian C, Kong FB,
Wei WY, Luo W, Xiao Q and Xie YB: Reversal of multidrug resistance
in gastric cancer cells by CDX2 downregulation. World J
Gastroenterol. 19:4155–4165. 2013. View Article : Google Scholar : PubMed/NCBI
|
40
|
Owen HC, Appiah S, Hasan N, Ghali L,
Elayat G and Bell C: Phytochemical modulation of apoptosis and
autophagy: Strategies to overcome chemoresistance in leukemic stem
cells in the bone marrow microenvironment. Int Rev Neurobiol.
135:249–278. 2017. View Article : Google Scholar : PubMed/NCBI
|
41
|
Beretta GL, Perego P and Zunino F:
Mechanisms of cellular resistance to camptothecins. Curr Med Chem.
13:3291–3305. 2006. View Article : Google Scholar : PubMed/NCBI
|
42
|
Chou HL, Fong Y, Lin HH, Tsai EM, Chen JY,
Chang WT, Wu CY, David Wang HM, Huang HW and Chiu CC: An acetamide
derivative as a camptothecin sensitizer for human non-small-cell
lung cancer cells through increased oxidative stress and JNK
activation. Oxid Med Cell Longev. 2016:91281022016. View Article : Google Scholar : PubMed/NCBI
|
43
|
Wu HM, Shao LJ, Jiang ZF and Liu RY:
Gemcitabine-induced autophagy protects human lung cancer cells from
apoptotic death. Hai. 194:959–966. 2016.
|
44
|
Zhang JW, Zhang SS, Song JR, Sun K, Zong
C, Zhao QD, Liu WT, Li R, Wu MC and Wei LX: Autophagy inhibition
switches low-dose camptothecin-induced premature senescence to
apoptosis in human colorectal cancer cells. Biochem Pharmacol.
90:265–275. 2014. View Article : Google Scholar : PubMed/NCBI
|
45
|
Li DD, Sun T, Wu XQ, Chen SP, Deng R,
Jiang S, Feng GK, Pan JX, Zhang XS, Zeng YX, et al: The inhibition
of autophagy sensitises colon cancer cells with wild-type p53 but
not mutant p53 to topotecan treatment. PLoS One. 7:e450582012.
View Article : Google Scholar : PubMed/NCBI
|
46
|
Amin A, Bajbouj K, Koch A, Gandesiri M and
Schneider-Stock R: Defective autophagosome formation in p53-null
colorectal cancer reinforces crocin-induced apoptosis. Int J Mol
Sci. 16:1544–1561. 2015. View Article : Google Scholar : PubMed/NCBI
|
47
|
Wu YT, Tan HL, Shui G, Bauvy C, Huang Q,
Wenk MR, Ong CN, Codogno P and Shen HM: Dual role of
3-methyladenine in modulation of autophagy via different temporal
patterns of inhibition on class I and III phosphoinositide
3-kinase. J Biol Chem. 285:10850–10861. 2010. View Article : Google Scholar : PubMed/NCBI
|
48
|
Fiorini C, Menegazzi M, Padroni C, Dando
I, Dalla Pozza E, Gregorelli A, Costanzo C, Palmieri M and
Donadelli M: Autophagy induced by p53-reactivating molecules
protects pancreatic cancer cells from apoptosis. Apoptosis.
18:337–346. 2013. View Article : Google Scholar
|
49
|
Sun Y, Liu Z, Zou X, Lan Y, Sun X, Wang X,
Zhao S, Jiang C and Liu H: Mechanisms underlying
3-bromopyruvate-induced cell death in colon cancer. J Bioenerg
Biomembr. 47:319–329. 2015. View Article : Google Scholar : PubMed/NCBI
|
50
|
Shin D, Kim EH, Lee J and Roh JL: RITA
plus 3-MA overcomes chemoresistance of head and neck cancer cells
via dual inhibition of autophagy and antioxidant systems. Redox
Biol. 13:219–227. 2017. View Article : Google Scholar : PubMed/NCBI
|
51
|
Joseph B, Ekedahl J, Lewensohn R,
Marchetti P, Formstecher P and Zhivotovsky B: Defective caspase-3
relocalization in non-small cell lung carcinoma. Oncogene.
20:2877–2888. 2001. View Article : Google Scholar : PubMed/NCBI
|
52
|
Zakeri Z and Lockshin RA: Cell death:
History and future. Adv Exp Med Biol. 615:1–11. 2008. View Article : Google Scholar : PubMed/NCBI
|
53
|
Lin SY, Chang YT, Liu JD, Yu CH, Ho YS,
Lee YH and Lee WS: Molecular mechanisms of apoptosis induced by
magnolol in colon and liver cancer cells. Mol Carcinog. 32:73–83.
2001. View Article : Google Scholar : PubMed/NCBI
|
54
|
Seo JU, Kim MH, Kim HM and Jeong HJ:
Anticancer potential of magnolol for lung cancer treatment. Arch
Pharm Res. 34:625–633. 2011. View Article : Google Scholar : PubMed/NCBI
|
55
|
Meschini S, Condello M, Calcabrini A,
Marra M, Formisano G, Lista P, De Milito A, Federici E and Arancia
G: The plant alkaloid voacamine induces apoptosis-independent
autophagic cell death on both sensitive and multidrug resistant
human osteosarcoma cells. Autophagy. 4:1020–1033. 2008. View Article : Google Scholar : PubMed/NCBI
|
56
|
Liu Y and Levine B: Autosis and autophagic
cell death: The dark side of autophagy. Cell Death Differ.
22:367–376. 2015. View Article : Google Scholar :
|
57
|
Shao J, Yang X, Liu T, Zhang T, Xie QR and
Xia W: Autophagy induction by SIRT6 is involved in oxidative
stress-induced neuronal damage. Protein Cell. 7:281–290. 2016.
View Article : Google Scholar : PubMed/NCBI
|
58
|
Lin W, Yuan N, Wang Z, Cao Y, Fang Y, Li
X, Xu F, Song L, Wang J, Zhang H, et al: Autophagy confers DNA
damage repair pathways to protect the hematopoietic system from
nuclear radiation injury. Sci Rep. 5:123622015. View Article : Google Scholar : PubMed/NCBI
|
59
|
Ray PD, Huang BW and Tsuji Y: Reactive
oxygen species (ROS) homeostasis and redox regulation in cellular
signaling. Cell Signal. 24:981–990. 2012. View Article : Google Scholar : PubMed/NCBI
|
60
|
Rouschop KM, Ramaekers CH, Schaaf MB,
Keulers TG, Savelkouls KG, Lambin P, Koritzinsky M and Wouters BG:
Autophagy is required during cycling hypoxia to lower production of
reactive oxygen species. Radiother Oncol. 92:411–416. 2009.
View Article : Google Scholar : PubMed/NCBI
|
61
|
Kaushik S and Cuervo AM: Autophagy as a
cell-repair mechanism: Activation of chaperone-mediated autophagy
during oxidative stress. Mol Aspects Med. 27:444–454. 2006.
View Article : Google Scholar : PubMed/NCBI
|
62
|
Tokarz P, Piastowska-Ciesielska AW,
Kaarniranta K and Blasiak J: All-trans retinoic acid modulates DNA
damage response and the expression of the VEGF-A and MKI67 genes in
ARPE-19 cells subjected to oxidative stress. Int J Mol Sci.
17:8982016. View Article : Google Scholar :
|
63
|
Liu EY, Xu N, O’Prey J, Lao LY, Joshi S,
Long JS, O’Prey M, Croft DR, Beaumatin F, Baudot AD, et al: Loss of
autophagy causes a synthetic lethal deficiency in DNA repair. Proc
Natl Acad Sci USA. 112:773–778. 2015. View Article : Google Scholar : PubMed/NCBI
|